3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Endocrine
2
Thoracic
1
NET
1
Head & Neck
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
Cyclophosphamide
908
Carboplatin
785
Paclitaxel
739
pembrolizumab
738
Cisplatin
707
Bevacizumab
705
Gemcitabine
619
Docetaxel
578
Rituximab
548
Radiotherapy
539
Dexamethasone
510
Nivolumab
485
Doxorubicin
444
Fluorouracil
392
Capecitabine
376
Etoposide
357
Pemetrexed
334
Cytarabine
334
Oxaliplatin
333
Lenalidomide
327
Prednisone
326
fludarabine phosphate
315
Erlotinib Hydrochloride
314
Trastuzumab
300
Leucovorin
299
fludarabine
296
Vincristine
287
Filgrastim
284
Bortezomib
284
Cetuximab
274
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Has results
×
fosbretabulin
×
Clear all
NCT02132468
2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2
Completed
18 enrolled
10 charts
NCT00653939
2015-02-09
FALCON
Mateon Therapeutics
Phase 2
Completed
63 enrolled
18 charts
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts